Alto Neuroscience, Inc.
ANRO · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $0 |
| Gross Profit | -$1 | $0 | -$0 | $0 |
| % Margin | – | – | – | 31% |
| R&D Expenses | $47 | $30 | $24 | $8 |
| G&A Expenses | $22 | $8 | $6 | $4 |
| SG&A Expenses | $22 | $8 | $5 | $4 |
| Sales & Mktg Exp. | $0 | $0 | -$0 | -$0 |
| Other Operating Expenses | -$1 | $0 | $0 | $0 |
| Operating Expenses | $68 | $38 | $29 | $12 |
| Operating Income | -$69 | -$38 | -$29 | -$12 |
| % Margin | – | – | – | -5,741% |
| Other Income/Exp. Net | $7 | $2 | $1 | $3 |
| Pre-Tax Income | -$61 | -$36 | -$28 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$61 | -$36 | -$28 | -$9 |
| % Margin | – | – | – | -4,374.8% |
| EPS | -2.5 | -1.35 | -1.08 | -0.36 |
| % Growth | -85.2% | -25% | -200% | – |
| EPS Diluted | -2.5 | -1.35 | -1.08 | -0.36 |
| Weighted Avg Shares Out | 25 | 27 | 26 | 26 |
| Weighted Avg Shares Out Dil | 25 | 27 | 26 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9 | $2 | $0 | $0 |
| Interest Expense | -$1 | $1 | $0 | $0 |
| Depreciation & Amortization | -$6 | $0 | $0 | $0 |
| EBITDA | -$69 | -$35 | -$27 | -$9 |
| % Margin | – | – | – | -4,305.7% |